ZBH has a higher market value than 93.2% of US stocks; more precisely, its current market capitalization is $29,363,806,607.
ZBH's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1,606.66 -- higher than 97.75% of US-listed equities with positive expected earnings growth.
ZBH's current price/earnings ratio is 800.1, which is higher than 98.96% of US stocks with positive earnings.
Stocks that are quantitatively similar to ZBH, based on their financial statements, market capitalization, and price volatility, are WLTW, PPG, AIG, LUV, and XYL.
ZBH's SEC filings can be seen here. And to visit Zimmer Biomet Holdings Inc's official web site, go to www.zimmerbiomet.com.
Zimmer Biomet Holdings designs, develops, manufactures, and markets orthopaedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. The company was founded in 1927 and is based in Warsaw, Indiana.
ZBH Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Zimmer Biomet Holdings Inc. To summarize, we found that Zimmer Biomet Holdings Inc ranked in the 17th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Zimmer Biomet Holdings Inc, consider:
Zimmer Biomet Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 89 -- greater than 96.8% of US stocks with positive free cash flow.
Zimmer Biomet Holdings Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.17. This coverage rate is greater than that of just 24.79% of stocks we're observing for the purpose of forecasting via discounted cash flows.
The weighted average cost of capital for the company is 11. This value is greater than 82.92% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ZBH, try EHC, ICUI, BHC, DHR, and TFX.
A new research study from “Data Bridge Market Research” with title Leigh Syndrome Treatment Insights 2020GlaxoSmithKline Plc, Brother Enterprises, Huazhong, Zhejiang Tianxin, Stryker Corporation, Zimmer Biomet Holdings, Inc., Wright Medical Technology, Inc., Integra LifeSciences Holdings Corporation among other domestic
WARSAW, Ind., Sept. 10, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2020….
All evidence indicates the medical technology sector hit its trough in April, as each month since has brought sequential improvement - from a springtime hole where elective medical procedures faced widespread suspensions. That meant growth slowed sharply in Q2 (-25.4% vs. Q1's -9.7%), and Needham expects declines to ease in...